TP53 and ovarian cancer: The formation of a complex between CSTF, BARD1/BRCA1 and TP53 has been reported to repress mRNA polyadenylation following treatment of cells with DNA-damage-inducing agents, suggesting that CSTF may have a direct role in the development of ovarian cancer [40].